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Abstract
Severe accidents caused by the ‘‘armed’’ spider Phoneutria nigriventer cause neurotoxic manifestations in victims. In
experiments with rats, P. nigriventer venom (PNV) temporarily disrupts the properties of the BBB by affecting both the
transcellular and the paracellular route. However, it is unclear how cells and/or proteins participate in the transient opening
of the BBB. The present study demonstrates that PNV is a substrate for the multidrug resistance protein-1 (MRP1) in cultured
astrocyte and endothelial cells (HUVEC) and increases mrp1 and cx43 and down-regulates glut1 mRNA transcripts in cultured
astrocytes. The inhibition of nNOS by 7-nitroindazole suggests that NO derived from nNOS mediates some of these effects
by either accentuating or opposing the effects of PNV. In vivo, MRP1, GLUT1 and Cx43 protein expression is increased
differentially in the hippocampus and cerebellum, indicating region-related modulation of effects. PNV contains a plethora
of Ca2+, K+ and Na+ channel-acting neurotoxins that interfere with glutamate handling. It is suggested that the findings of
the present study are the result of a complex interaction of signaling pathways, one of which is the NO, which regulates
BBB-associated proteins in response to PNV interference on ions physiology. The present study provides additional insight
into PNV-induced BBB dysfunction and shows that a protective mechanism is activated against the venom. The data shows
that PNV has qualities for potential use in drug permeability studies across the BBB.
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Introduction
Accidents involving the ‘‘armed’’ spider Phoneutria nigriventer
can cause neurotoxic manifestations, which in severe cases may
include convulsion [1]. In experiments involving rats, P.
nigriventer venom (PNV) impairs the BBB by increasing
endothelial transcellular vesicular transport mediated by microtu-
bules [2] and by down-regulation of inter-endothelial junctional
proteins [3,4]. In astrocytes, PNV induces swelling of the
perivascular end-feet [5], increases cytoskeletal GFAP and S-100
calcium metabolism-associated protein expression [6], and upre-
gulates aquaporin-4 [7], a water channel-forming protein involved
in edema formation and resolution. In neurons, PNV causes cFOS
induction [3] and upregulation of VEGF and Flt-1 and Flk-1
receptors [8,9]. Increased understanding of the mechanisms
involved in BBB dysfunction caused by PNV is beneficial from a
medical perspective.
In the present study, MRP1 efflux pump activity was examined
in cultured astrocytes and endothelial cells (HUVEC lineage)
incubated with PNV. The effect of PNV on the mRNA transcripts
of mrp1, glut1 and cx43 in astrocytes and the mediation of NO in
the same was also analyzed. In vivo, the expression of these
proteins was examined in the hippocampus and cerebellum of rats
at different time-points following PNV exposure. The present
study is of interest as investigations into the effect of animal venom
on the BBB are rare. The use of PNV as a pharmacological tool to
manipulate BBB can provide new insights on the changes that
occur at the blood-brain interface. Spider venoms represent a rich
mixture of proteins, peptides, neurotransmitters and small
molecules with specific, highly potent effects on the nervous
system of their prey or predators [10]. P. nigriventer venom
contains Ca2+, K+ and Na+ channel-acting neurotoxins that affect
neurotransmitter release and uptake [11]. Therefore its instru-
mental use for pharmacological characterization of proteins
associated with the functioning of the BBB could be important
for evaluating the possible therapeutic potential of PNV in
neurochemical disturbances [10,12,13]. A positive factor is that
severe envenomation by P. nigriventer occurs in less than 0.5% of
accidents involving humans [1], and that in experimental cases the
effects of PNV are resolved in a few hours. Thus it is important to
further investigate the effect of PNV-induced BBB opening, taking
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into consideration the pharmacological usefulness of the venom for
drug permeability studies across the BBB. The study also
contributes to a greater understanding of the envenomation
profile of accidents involving P. nigriventer.
Material and Methods
Animals
In vitro assays used newborn Wistar rats (Rattus norvegicus, 0–2
days old) for harvesting astrocytes and in vivo assays used male
Wistar rats (250–300 g), all obtained from an established colony
maintained by the Multidisciplinary Center for Biological Investi-
gation (CEMIB) at UNICAMP. Animals were kept in a 12/12 hour-
light/dark cycle with food and water supplied ad libitum. The
experiments were approved by the Institutional Committee for
Ethics in Animal Use (CEUA, protocol no. 1429-1) and followed the
Brazilian College for Animal Experimentation (COBEA) guidelines.
Purified astrocyte primary cultures and HUVEC cells
A primary culture of cerebral cortical-derived astrocytes was
purified from 0–2 day-old newborn Wistar rats as previously
described [4,14]. Human umbilical endothelial cell lines (HU-
VEC, ATCC #CRL-1730, Manassas, VA, USA) were cultured in
DMEM containing 10% fetal bovine serum (FBS), supplemented
with 100 U/ml penicillin, 100 mg/ml streptomycin, and propa-
gated at 37uC in a 5% CO2 humidified atmosphere. Cells were
seeded onto 24-well cell culture plates (104 cells/well).
In vitro MRP1 efflux activity after treatment with PNV or
PNV plus nNOS blocker
Measurement of MRP1 activity in astrocytes and HUVEC was
performed using a fluorescein substrate. Astrocytes or HUVEC
were placed in a 6-well plate and treated with DMEM (control),
PNV (14.6 mg/ml), only 7NI (control) or PNV plus 7NI (1 mg/ml)
for 5 h. In the last two hours of treatment, a fluorescein substrate
(100 mM) was added to the cells (uptake phase). The cells were
then washed with PBS and incubated for 15 min in a completely
fresh medium, without fluorescein, to allow fluorescein efflux by
MRP1 (efflux phase). To evaluate the effect of PNV, PNV plus
7NI, and 7NI directly on MRP1 activity, these were added only
during the efflux phase, for 15 min. Fluorescein fluorescence was
assessed by flow cytometry analysis within the live-gate, using
FACScalibur (Becton and Dickinson - BD, Franklin Lakes, NJ,
USA). Data was analyzed using Cell Quest Pro software (Becton
and Dickinson – BD). The values correspond to the maximum
fluorescence resulting from fluorescein uptake and are expressed in
Relative Fluorescence Units (RFU). The values were obtained
through three sets of experiments.
In vitro mrp1, glut1 and cx43 mRNAs expression in
astrocytes treated with PNV or PNV plus nNOS blocker
Cultured astrocytes were treated with 1) DMEM (control); 2)
14.6 mg/ml of PNV freshly-diluted in DMEM [2]; 3) 7NI
Table 1. Sequences of primers of gapdh, cx43, mrp1 and glut1.
Primer Sequence
NCBI Reference
number
gapdh 59 GGCTCTCTGCTCCTCCCTGTTCT 39 NM_017008.3
59 CCGTTCACACCGACCTTCACCATC 39
cx43 59 CTTCAGCCTCCAAGGAGTTCCACCA 39 NM_012567.2
59 CAGTCACCCATGTCTGGGCACC 39
mrp1 59 GATGGCTCCGATCCGCTCTGG 39 NM_022281.2
59 GGCACCCATGTGAGGACCGTATTCT 39
glut1 59 GTTTCACAGCCCGCACAGCTTGA 39 NM_138827.1
59 GCCCCTCCCACGGCCAACATA 39
doi:10.1371/journal.pone.0107292.t001
Figure 1. MRP1 activity in astrocytes (A) and endothelial cells
HUVEC (B). The activity of MRP1 was assessed by flow cytometry
through the fluorescein substrate. The values correspond to the
percentage of fluorescence intensity into the cells of the Uptake
sample, the maximum fluorescence obtained, and were expressed in
Relative Fluorescence Units. In astrocytes, PNV induced immediate
(15 min after exposure) decrease in the cellular fluorescence, indicating
that MRP1 efflux activity was improved, compared with control; 5 h
following envenoming, cells maintained MRP1 activity, although it was
not as intense as at 15 min. 7NI+PNV treatment (for 15 min) also
induced MRP1 activity in astrocytes, however this treatment for 5 h
stopped efflux activity. 7NI per se (both at 15 min or 5 h) did not induce
efflux activity. In endothelial cells, PNV induced a decrease in
fluorescence at 15 min time-point, but not at 5 h. 7NI+PNV induced
more significant MRP1 activity both at 15 min and 5 h in endothelial
cells. 7NI treatment per se (used as a control of 7NI/PNV) showed no
change in the MRP1 activity relative to 7NI/PNV. The values correspond
to the values of three independent experiments. *p,0.05, **p,0.01,
***p,0.001, compared to control cells. Data was analyzed by one-way
ANOVA, followed by the Tukey-Kramer post-test.
doi:10.1371/journal.pone.0107292.g001
Protection against Phoneutria nigriventer Spider Venom in the Brain
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e107292
(control); 4) PNV plus selective nNOS blocker, 7-nitroindazole
(7NI, 1 mg/ml) [15] for 2 h at 37uC. The mRNAs of the three
proteins were measured. Then, astrocytes (,16106 cells) were
trypsinized, washed and the total RNA was extracted using a
commercial extraction kit in accordance with the manufacturer’s
instructions (Absolutely RNA Miniprep-GE). The concentration of
isolated RNA samples was assessed by molecular absorption
spectroscopy in the UV region, at 260 nm, and purity was assessed
by calculating the ratio between absorbance at 260/280 nm. The
reverse transcription from each sample (1 mg of total RNA) was
performed with AffinityScript QPCR cDNA Synthesis Kit (Agilent
Technologies, Santa Clara, CA, USA) in accordance with
manufacturer’s instructions. Reverse transcription was carried
out at 25uC for 5 min, and the products were then extended at
42uC for 30 min to allow cDNA synthesis. Finally, the reaction
was terminated by heating at 95uC for 5 min. Samples without
reverse transcriptase were processed in parallel and served as
negative controls. The effect of PNV on the expression of several
genes encoding MRP1, GLUT1 and Cx43 proteins was investi-
gated by qRT-PCR using the Brilliant II SYBR Green QPCR
Master Mix on Mx3005P QPCR Systems (Agilent Technologies).
Thermal cycling conditions were as follows: 10 min at 95uC
followed by 40 amplification cycles at 95uC for 30 s, 55uC for one
min and 72uC for one min. Depending on the type of primer, each
reaction was performed using 1.0, 0.5 or 0.25 mM of forward and
reverse primer and 100 ng of cDNA template in a final reaction
volume of 25 ml. Melting curve analysis was performed at the end
of the PCR to verify the identity of the products. The denaturation
temperature was determined at the end of the amplification
program, in a dissociation protocol that consisted of gradual 60uC
to 95uC temperature increase at 0.5uC steps. The initiators were
delineated based on the mRNA sequence described in Table 1.
Additionally, whenever possible, PCR primers were designed to
span adjacent exons in order to prevent amplification of the
intron-containing genomic DNA. An efficiency curve was carried
out for each primer using the serial dilution method. All
quantifications were normalized to the housekeeping gene
GAPDH and evaluated based on the control group from the Ct
of these groups for each tested gene. A non-template control with
non-genetic material was included to eliminate contamination or
nonspecific reactions. Each sample was tested in duplicate and
then used for the analysis of the relative transcription data using
Figure 2. Effect of PNV and involvement of neuronal nitric oxide synthase in expression of mrp1, glut1 and cx43 genes, in astrocyte
primary culture, by Real Time PCR. PNV increased mRNA levels of mrp1 and nNOS blockade by 7NI counteracted this effect. glut1 mRNA was
decreased by PNV, but 7NI+PNV treatment also neutralized this PNV effect. However, cx43 mRNA level was increased by PNV and even more by 7NI
plus PNV. In 7NI per se treated-astrocytes mrp1 gene expression was significantly above the level found in cell treated with 7NI/PNV; in contrast, glut1
and cx43 gene expression of astrocytes treated with 7NI alone was significantly below the level found in 7NI/PNV-treated cells. Fold change in genes
expression was analyzed by the 22DDCT method. Graphs showed relative gene expression, considering control as 1 (dotted line in graphs). Data is
mean 6 S.D.M. (**p,0.01 and ***p,0.001 vs. Control; ###p,0.001 vs. PNV; NNNp,0.001 vs. 7NI/PNV).
doi:10.1371/journal.pone.0107292.g002
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the 22DDCT method [16], taking into account the efficiency of
each primer [17].
In vivo assays: Western blotting and
immunofluorescence of MRP1, GLUT1 and Cx43
The animals (250–300 g) were divided into two groups. One
group received a single intravenous (i.v.) injection of PNV
(850 mg/kg in 0.5 ml) [5] in the tail vein, while the control (sham)
group received the same volume of 0.9% sterile saline solution. At
30615 min, 2 h and 5 h post-injection (n = 5/time interval) the
animals were killed with a 3:1 i.p. overdose of ketamine chloride
(Dopalen; 100 mg/kg) and xylazine chloride (Anasedan; 10 mg/
kg) anesthetics (Vetbrands, Jacarei, SP, Brazil). This time-window
refers to the period of acute intoxication of the rats and their
ongoing clinical recovery from a toxic condition [18].
Western Blotting (WB). Deeply-anesthetized (CO2 inhala-
tion) animals were euthanized by decapitation. Cerebella and
hippocampi were quickly dissected and homogenized in lysis
buffer (10 mM EDTA, 2 mM PMSF, 100 mM NaF, 10 mM
sodium pyrophosphate, 10 mM NaVO4, 10 mg of aprotinin/ml
and 100 mM Tris, pH 7.4). Because control animals were alive
and did not show signs of clinical impairment, their hippocampi
and cerebella (from 30615 min, 2 h or 5 h time-points) were
mixed and homogenized to form a control pool (n = 15). The
expression of proteins of the control pool was compared with the
PNV-30 615 min, PNV-2 h or PNV-5 h (n = 5 per time) group.
Homogenates were processed and underwent immunoblotting as
described [6]. Briefly: after centrifugation (3000 g/10 min), the
supernatant was collected and stored at 270uC. The proteins
(50 mg) were separated on sodium dodecyl sulfate-polyacrylamide
and electrophoretically transferred onto the nitrocellulose mem-
brane (BioRad Laboratories, ref. 162-0115). After overnight
blocking (5% non-fat milk) the membranes were incubated at
room temperature for 4 h with primary antibodies described in
Imunofluorescence sub-section (MRP1 – 1:200; GLUT1 – 1:400;
Cx43 – 1:600 dilutions), followed by secondary horseradish
peroxidase-antibodies (1:1000, Sigma). The blots were revealed
using a chemiluminescence reagent (Super Signal, Pierce) and X-
ray film (Fuji Medical, Kodak, Ref Z358487-50EA). Each band
was quantified by densitometry using the IMAGEJ software
(version 1.33u, NIH, USA). For each protein studied the results
were confirmed in three sets of experiments. The blots were then
stripped and reprobed for anti-b-actin analysis (1:250, Sigma) as a
loading control for the other protein blots. Negative control was
provided by omitting the primary antibody.
Immunofluorescence (IF). Rats were deeply anesthetized
and then sequentially perfused transcardially with 150 ml of
physiologic solution followed by fixative ((250 ml of ice-cold 0.1 M
phosphate-buffered saline (PBS) containing 4% paraformaldehyde,
pH 7.4)). The brains were dissected, frozen in liquid N2 and
cryoprotected with 15% and 30% sucrose solution (24 hours
each). Cryosections (12 mm thick) were mounted on silane-coated
glass slides, air dried and then permeabilized with 0.1% Triton X-
100 for 10 min at room temperature (RT) (only for GLUT1,
before Triton X-100, the slices were incubated with ethanol,
followed by methanol, for 10 min each, at 220uC), followed by
0.1% Tween 20 in TBS containing 5% non-fat milk at RT for 1 h.
Subsequently, sections were reacted with anti-MRP1 (Zymed,
187246 - 1:100), anti-GLUT1 (Alpha Diagnostic, GT11-S -
1:100), anti-Cx43 (Sigma, C6219 – 1:500) and GFAP (Dako
Cytomation, CA, USA, ZO 334 – 1:100) at 4uC (for GLUT1 only
the incubation lasted 2 h in RT), and with FITC- or TRITC-
conjugated polyclonal secondary antibody (Anti-rabbit IgG
TRITC conjugate – T5268 – 1:1500; Anti-mouse IgG FITC
conjugate – F6257 – 1:1500, Sigma) at RT for 1 h in the dark. Six
images/animal ( = 30 images/time) were captured at random
using a fluorescence BX51TF microscope (Olympus Optical C.
Ltd., Tokyo, Japan) equipped with Image-Pro Plus 6.0 image
analyzer software (Media Cybernetics Inc., USA). Quantification
of the protein expression was performed with enhanced contrast
and the density slicing feature of IMAGEJ software (version 1.33u,
NIH, USA), which measures the intensity of immunofluorescence.
Four sections per animal at each of the time-points (n = 5 animals
per time = 20 sections/time) for the control and envenomed
groups, were immunolabeled. The integrated density of pixels was
measured by the total area (0.35 mm2) of captured images by C.R.
and P.A.M.O. (double blinded measure).
Statistical analysis
The results were expressed as mean 6 S.E.M. or mean 6
S.D.M. All the numerical data were analyzed using the GraphPad
Prism software package. One-way analysis of variance (ANOVA)
followed by the Tukey-Kramer post-test was used to compare data
from the control and PNV-treated samples. Statistical significance
was set at p,0.05. Unpaired t-Student was used to compare each
treatment with control.
Results
In vitro experiments: MRP1 activity
PNV-treated astrocytes. Fluorescence intensity was de-
creased significantly at 15 min comparing with DMEM-treated
cells (control), suggesting efflux activity. At 5 h, the fluorescein
efflux remained significant relative to control, but removal had
decreased relative to PNV-15 min, indicating time-dependent
MRP1 efflux activity (Figure 1A).
7NI/PNV-treated astrocytes. The fluorescence intensity
was decreased significantly at 15 min relative to control
(DMEM-treated) indicating fluorescein removal, whereas there
was no difference relative to fluorescein removal at 5 h, thus
indicating that the effect of nNOS-derived NO on the MRP1-
efflux activity is time-dependent in isolated astrocytes (Figure 1A).
PNV-treated HUVEC. Fluorescence was significantly lower at
15 min after PNV exposure compared to control cells, but at 5 h
the removal of fluorescein had diminished, thus indicating no
significant difference relative to DMEM-treated HUVEC. This
suggests that PNV treatment affects MRP1 activity time-depen-
dently (Figure 1B).
7NI/PNV-treated HUVEC. Relative to the DMEM control,
MRP1 efflux activity decreased significantly at 15 min post-
treatment; the decrease was greater than in cells treated with PNV
alone, thus indicating that the removal of fluorescein was
potentiated in the absence of nNOS-derived NO. Interestingly,
cells where removal activity had stopped after 5 h of treatment
with PNV alone, when treated with 7NI+PNV for 5 h resulted in a
significant decrease of fluorescence intensity, indicating reactiva-
Figure 3. Western blotting for MRP1, GLUT1 and Cx43 in cerebellum (CER) and hippocampus (HIP). The time course of PNV treatment
(15–459, 2 and 5 h) was compared with control group. MRP1 expression was increased 5 h after envenoming in hippocampus. GLUT1 expression
increased in PNV-5 h time-point, in both regions. No significant difference was observed in Cx43 expression. Values represent the mean 6 S.E.M. The
results were confirmed in three sets of experiments. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0107292.g003
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tion of MRP1 activity (Figure 1B). The findings seem to indicate
that NO signaling re-activates efflux exhaustion of MRP1.
7NI-treated astrocytes and HUVEC. 7NI alone, used as
control, did not show significant differences in the MRP1 efflux
activity when compared with that of 7NI/PNV, in two tested
periods (15 min and 5 h), in both astrocytes and HUVEC cells.
In vitro experiments: Quantitative Real Time-PCR (qRT-
PCR) analysis
mrp1. PNV-treated astrocytes showed a 38% increase of
mrp1 mRNA level at 2 h. Treatment with 7NI plus PNV
significantly counteracted the effects of PNV leading to a 67%
reduction below the level found in PNV-treated cells and a 29%
reduction relative to baseline (Figure 2A). In the 7NI-treated
astrocytes mrp1 gene expression was significantly above the level
found in cells treated with 7NI/PNV, but significantly below that
found in PNV-treated cells.
glut1. PNV decreased glut1mRNA by 20% below baseline in
cultured astrocytes. The inhibition of nNOS (7NI/PNV-treated
astrocytes) reversed this effect by promoting a 12% increase above
baseline and a 32% increase compared to PNV-treated cells
(Figure 2B). 7NI per se decreased glut1 gene expression in relation
to 7NI/PNV treatment; however, the decrease was minor than the
found in PNV-treated cells.
cx43. Two hours of PNV exposure induced a 25% increase in
cx43 mRNA in astrocytes, compared to the physiological level of
untreated cells. Co-exposure of 7NI + PNV elevated the mRNA
expression to 56% above baseline and 26% above the level found
in PNV-treated astrocytes (Figure 2C). Incubation with 7NI alone
significantly decreased gene expression compared with 7NI/PNV
treated cells.
In vivo experiments: WB data
MRP1. While hippocampal MRP1 level increased by 70% in
PNV-treated rats at 5 h, in the cerebellum the protein level
remained unchanged at all post-envenoming time-points (Fig-
ure 1A, B, C).
GLUT1. At 5 h following treatment of rats with PNV
increases of 81% and 32% were observed in the hippocampal
and cerebellar GLUT1, respectively, relative to saline-treated rats
(Figure 3D, E, F).
Cx43. The total level of the main gap junction-forming
protein remained unchanged in the hippocampus and cerebellum
throughout the time-points post-PNV envenoming (Figure 3G, H,
I).
In vivo experiments: IF data
MRP1. MRP1 immunolabeling appeared as fluorescent dots
outlining the endothelial wall of the hippocampal and cerebellar
microvessels. At 5 h, PNV-treated animals showed a 62% increase
in the MRP1 expression in hippocampus and a 66% increase at
2 h in the cerebellum in relation to respective control group
(Figure 4A–J).
GLUT1. Anti-GLUT1 immunolabeling was tenuous and
discontinuous around vessels in controls; PNV promoted 80%
(2 h) and 102% (5 h) significant increases in anti-GLUT1
reactivity around vessels and across the parenchyma, mainly in
the hippocampus (see (*)). In the cerebellum of PNV-treated rats,
anti-GLUT1 was increased at 5 h, compared to control
(Figure 5A–J).
Cx43. In the control group, Cx43 immunoreactivity outlined
microvessels in the hippocampus and cerebellum. This was faint in
the Purkinje and granular layers (Figure 6A and 6F). PNV
treatment induced an immediate enhancement of labeling in both
layers followed by a gradual decrease (Figure 6B–D and 6G–I).
Comparing with the control group, the quantification of pixel
density (Figure 6E,J) showed a 56% increase in the hippocampus
and a 64% increase in the cerebellum in anti-Cx43 staining,
followed by a 200% decrease below baseline (5 h) in the
hippocampus only.
Cx43 and GFAP. In order to show that increases of Cx43
level paralleled with increases of GFAP in PNV-treated rats,
frozen sections of the cerebellum (Figure 7) and hippocampus (not
shown) were immunostained for GFAP and Cx43. Compared to
controls (panels A, B, C, D), animals exposed to PNV showed an
immediate (at 15–45 min) increase in the expression of Cx43 (see
also IF and WB data) and induced GFAP expression in reactive
astrocytes (panels E, F, G, H). Co-localization of Cx43 and GFAP
was intense around Purkinje cells, granule neurons, the wall of
vessels, and in astrocytic processes within the molecular layer. As
expected, while Cx43 labeling appeared as serial dots, GFAP
labeling was continuous, since gap junctions form isolated
communicating channels in the plasma membrane, while GFAP
is part of the intermediate filaments of the glial cytoskeleton
distributed along the astrocyte processes and perikaryum. In the
hippocampus, GFAP and Cx43 labeling increased around blood
vessels and throughout the hippocampal parenchyma (not shown).
Discussion
The results of the present study found that P. nigriventer
armed-spider venom is a substrate for MRP1 activity in
endothelial and astrocyte cells. PNV also affected the expression
of mrp1, glut1 and cx43 mRNAs transcripts in astrocytes.
Furthermore, evidence suggests that NO derived from nNOS
could synergistically and/or antagonistically mediate the PNV
effects. In vivo, the venom alters the translational expression of
MRP1, GLUT1 and Cx43 proteins in the microvessel wall. Cx43
upregulation was detected in reactive astrocytes of the cerebellum
and hippocampus and outlining the Purkinje neurons. All of these
effects were time- and cell/region-modulated. To the best of the
authors’ knowledge this is the first study to show alterations of
these proteins by spider venom that disrupt the BBB, and that is
also known to affect other neurovascular systems [13].
The present immunohistochemistry-based in vivo MRP1
labeling is in conformity with its strategic location at the ECs of
brain microvessels [18] and end-feet processes of astrocytes
[19,20]. In vitro, the ready increase in MRP1 activity in ECs
and astrocytes as early as 15 min after venom exposure coincides
with the onset of signs of serious intoxication of the animals. The
increase in MRP1 efflux activity suggests a rapid induction of a
pro-homeostasis protective mechanism. However, 51h later,
endothelial cells no longer showed efflux activity while astrocytes
showed activity deceleration in comparison with that seen at
15 min. Clinically, at this time-point the animals showed signs
indicating that recovery of intoxication is underway [6,21]. The
Figure 4. Immunofluorescence (IF) for MRP1 in hippocampus (A–D) and cerebellum (F–I). MRP1 labeling was increased in hippocampus
after 5 h of envenoming. In the cerebellum, PNV-2 h showed an increase in MRP1. E and J show IF densitometric values for the hippocampus and
cerebellum, respectively (*p,0.05 relative to control). Values represent the mean 6 S.E.M. The results were confirmed in three sets of experiments.
v = blood vessel. N = 5 per group. Bar = 35 mm.
doi:10.1371/journal.pone.0107292.g004
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absence of MRP1 activity in ECs and its slowdown in astrocytes at
5 h may imply that an appreciable amount of venom has been
pumped out or that the efflux mechanism has undergone
interference of second messengers, or both.
One such candidate is nitric oxide, a second messenger already
known to affect transport at the blood-brain interface [22–24].
MRP1 belongs to the ATP-driven efflux pump family of
transmembrane multidrug resistance-associated proteins (MDR)
which mediate the removal of cytotoxic substances and drugs from
the CNS. MRP1 acts as a glutathione S-conjugate efflux pump
(GS-X pump) by transporting organic anions and several drugs
which are conjugated with glutathione (GCH) [25]. The present
findings found that nNOS-derived NO could be one of the
mediators of the PNV effect at the BBB, and that the mediation is
modulated according to the type of cells and time of venom
exposure. The involvement of the nNOS/NO system has been
already described to mediate the cavernosal relaxation induced by
PnTx2-6, a toxin isolated from PNV [13,26]. Therein, the toxin
neurovascular effect was potentiated by NO produced by nNOS.
In the present study, the co-treatment of ECs with PNV plus the
selective nNOS inhibitor (7NI) not only promoted enhancement of
efflux activity at 15 min but reactivated pump activity at 5 h. The
improvement of pump activity in the absence of nNOS-derived
NO suggests that at that time-point (5 h) the NO dampens efflux
activity, so working antagonistically to the efficiency of toxicant
removal in ECs. Conversely, on the glial cells, the effect of NO
seems to contribute positively to the removal of the toxicant, since
MRP1 efflux activity in astrocytes treated with 7NI + PNV, which
was in process in cells incubated with PNV alone, stopped efflux
activity in the absence of NO produced by nNOS. Such effect was
time-dependent, as it was only found at 5 h. At 15 min, efflux
activity was maintained in 7NI/PNV-treated astrocytes equal to
that found in PNV-treated cells. The findings suggest that NO
intervention in MRP1 activity can be temporally diverse and can
depend on cell-type. The results also show that astrocytes possess a
more efficient mechanism for substrate (PNV) extrusion than the
peripheral ECs used herein. Available literature indicates that the
amount of MRP1 is greater in astrocytes than in the brain ECs of
rats [27,28] leading to the conclusion that astrocytes possess an
efficient mechanism against drug (PNV) accumulation.
Besides NO, other mechanisms could affect the temporal-
related MRP1 activity changes. The possibility that the pump
could be rendered defective by the toxic accumulation of PNV
inside the astrocytes or by failure in the conjugation of GSH, or
another reason, cannot be discarded. In fact, relevant evidence
shows that the transporter activity of MRP1 can be caused by
endogenous-induced alterations in the glutathione metabolism
[29–31]. Relevant literature reports links between MRP1 drug
resistances vs. GSH cellular levels vs. drug-metabolizing cyto-
chrome P-450 (CYP) induction in response to xenobiotics. CYP
enzymes encompass a super-family of hemoproteins that play a
role in the biotransformation of a wide range of endogenous and
exogenous compounds [32]. CYP induction in response to
xenobiotics occurs concomitantly with the generation of free
radicals and depletion of intracellular GSH content [29,30]. This
hinders MRP1 activity as it requires conjugation or co-transpor-
tation of drugs and organic ions with GSH. The presence of the
drug-metabolizing cytochrome P450 in cultured endothelial cells
and primary astrocytes [29,33] and in the wall of blood vessels,
astrocytes of the cerebellum and pyramidal neurons of all
hippocampal subfields [34,35] evidences the existence of endog-
enous alterations in GSH levels, and hence in MRP1 activity.
The inhibition of MRP1 activity has been also reported to occur
through changes in the conformation of the MRP1 molecule
[25,36]. However, this did not seem to be the case in the present
study, the data of which indicates that mrp1 gene activity
remained active, since mrp1 mRNA increased in cultured
astrocytes treated with PNV (Figure 2). In agreement, the
translational event was not affected, since PNV-treated rats
showed increased expression of MRP1 in the hippocampus and
cerebellum (Figure 3 and 4). Altogether, the data cast doubt on the
capacity of MRP1 to make conjugates and export them from
PNV-treated cells. Further studies are necessary to clarify this, and
to verify GSH stores inside the cells.
In relation to mediation by NO, it was noted that at the
transcription level NO acted proactively in relation to MRP1
transcription, since in the absence of NO-derived nNOS (7NI+
PNV-treated astrocytes) mRNA expression decreased significantly
relative to both control and PNV-treated astrocytes. The data
suggests that the gas acts synergistically with PNV promoting the
increase of mrp1 mRNA transcripts. This is worthy of note
because in relation to MRP1 activity, NO inhibits the extrusion
activity of the protein.
The complexity of NO mediation was also seen in relation to
the influx transporter, GLUT1. 7NI+PNV treatment increased
glut1 gene expression which had been reduced by PNV alone.
The finding reveals that NO produced by nNOS may have had a
critical role in a possible reduction of the facilitative glucose
transporter promoted by the spider venom and hence in a
supposed lower supply of energy fuel from astrocytes for brain
metabolism [37]. Nevertheless, the hippocampus and cerebellum
of rats treated with PNV showed increased expression of GLUT1
indicating that translational events were stimulated by the venom.
Such apparent discrepancy may be attributed to in vitro versus in
vivo experiments and different time scales, but also to sometimes
divergent regulatory mechanisms acting at the translational stage
and respective coding gene [38].
Little has been reported about interaction between multidrug
resistance protein and glucose transporter protein. However, it is
conceivable that cytotoxic insult to the CNS would demand
greater resources of glucose and a mechanism for eliminating the
toxic agent. In fact, studies in in vitro cell lines have shown an
increased rate of facilitative glucose transport and level of GLUT1
expression in parallel with increased vincristine resistance, active
vincristine efflux and decreased vincristine steady-state accumula-
tion. Moreover, glucose transport inhibitors (cytochalasin B and
phloretin) block the active efflux and increase steady-state
accumulation of vincristine [39]. Contrastingly, increased expres-
sion/content of GLUT1 reflects elevated levels of circulating
glucose, and the increase of brain glucose utilization has been
correlated positively with elevated expression of GLUT1 and vice-
versa [40]. It may be suggested that significant increases of
GLUT1 in the hippocampus and cerebellum of PNV-treated rats
could be evidence of enhanced glucose transport and probable
high energy metabolism demand after envenomation. The
significant increase of glut1 transcripts after the inhibition of
Figure 5. Immunofluorescence (IF) for GLUT1 in hippocampus (A–D), and cerebellum (F–I). In hippocampus, GLUT1 immunolabeling
increased 2 and 5 hours after envenoming. In the cerebellum, no significant changes were observed. E and J show the IF densitometric values for the
hippocampus and cerebellum, respectively (*p,0.05, **p,0.01 relative to control). Values represent the mean6 S.E.M. The results were confirmed in
three sets of experiments. v = blood vessel, * = labeled parenchyma. N = 5 per group. Bar = 35 mm.
doi:10.1371/journal.pone.0107292.g005
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Figure 6. Immunofluorescence (IF) for Cx43 in hippocampus (A–D) and cerebellum (F–I). Cx43 expression was increased after 15–459 in
the hippocampus and cerebellum. In the hippocampus, there was an intense decrease after 5 h of envenoming. E and J show the IF densitometric
values for hippocampus and cerebellum, respectively (*p,0.05, **p,0.01 compared to control). Values represent the mean6 S.E.M. The results were
confirmed in three sets of experiments. v = blood vessel; * = labeled parenchyma; GL – glomerular layer; ML – molecular layer; PCL = Purkinje cell
layer. Bars = 70 mm (A–D, F, G, I); 35 mm (H).
doi:10.1371/journal.pone.0107292.g006
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nNOS revealed that NO mediation is synergic with PNV against
facilitative glucose transport. The results of the present study
indicate that PNV is a useful tool for research into MDR
phenotype development, drug efflux and glucose uptake mecha-
nisms.
PNV increased cx43 gene expression, an effect that was
potentiated by the absence of NO produced by nNOS. The
increases in the cx43 transcripts suggest increased preparation for
translational events, with NO antagonistically mediating the effects
of PNV. The increase in cx43 gene activity in vitro paralleled
increases in Cx43 protein expression, though the latter was only
observed through the density of pixels of anti-Cx43 labeling (IF
data) but not in the total amount of protein in the hippocampus
and cerebellum (WB data). The lack of significance obtained from
WB analysis indicates that the formation of new intercellular
channels is not uniform throughout the cerebellum and hippo-
campus parenchyma as previously reported [41]. In fact, the
increase of Cx43 immunoreactivity was marked around blood
vessels and around Purkinje and granule neurons but less
expressive in the molecular layer of the cerebellum (Figure 7).
Figure 7. Cx43 and GFAP imunofluorescence in sections of cerebellum. A, C, E, G represent Cx43 and B, D, F, H represent GFAP
immunolabeling. A–D showed control group and E–H showed PNV-15-459 group. There is a correlation between Cx43 and GFAP labeling (arrows and
arrowheads). This indicated that Cx43 are positive mainly in astrocytes. G = Granular layer, P = Purkinje layer, M = Molecular layer, v = blood vessel.
Bar = 70 mm for all panels.
doi:10.1371/journal.pone.0107292.g007
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Such increases in Cx43 expression occurred 15 to 45 min after
envenomation when animals already manifested signs of intense
intoxication [4,8,21]. At subsequent time-points, Cx43 staining
underwent a major reduction in the hippocampus and showed a
tendency for reduction in the cerebellum (Figure 6), coincidently
with amelioration of the toxic condition of the animals [4,8,21].
The increase of Cx43 protein expression implies the establishment
of intercellular channels for diffusion of chemical and electrical
information between the reactive (GFAP+) astrocytes [42].
Connexin 43-formed channels are strictly linked to modifications
of ionic composition of extracellular CNS compartment, with
calcium oscillations possessing a critical role [43]. PNV contains
excitotoxic neuropeptides [11] and PnTx1-3, a neurotoxin isolated
from PNV, has been shown to increase the frequency of Ca2+
oscillations in in vitro GH3 cells [44]. The significant further
reduction of Cx43 expression, especially in the hippocampus (5 h
post-PNV), could be a mechanism for avoiding cell damage [45],
since PNV induces FOS induction (2 h post-PNV) in neurons [6]
and the decrease of gap junctions (GJs) formation/communication
in astrocytes could be controlled by neurons [42].
A further interesting point is the relationship between Cx43 and
glucose metabolism. Molecular pathways suggest a potential link
between GJs and energy metabolism in astrocytes. Studies have
shown that the inhibition of Cx43 increases glucose transport by
astrocytes through GJs [46] and up-regulation of GLUT1 [47],
which is then associated with up-regulation of Na+/K+-ATPase
activity [48]. The basis of this relationship is still unknown, but
could be related to the blocking effect of PNV on K+ channels
[11]. The data indicates that PNV is instrumental for studies
related to the interaction of Cx43, GLUT1 and MRP1.
In conclusion, the present study shows that the PNV is a
substrate for MRP1 activity. Also, the study provides evidence that
nNOS-derived NO is involved in the mediation of PNV effects,
apparently through a complex dual mediation at the BBB level: as
an enhancer of mrp1 transcription in astrocytes and as an inhibitor
of MRP1 efflux activity in endothelial cells. Data showing
differences between the type of cells and between the hippocampus
and cerebellum, two regions in which PNV disrupts the BBB, is
interesting as it allows the detection of regional differences in
energy metabolism, capacity for drug exclusion/distribution and
communication between cells in PNV-intoxicated rats. The study
not only provides information for therapeutic purposes in relation
to victims of Phoneutria nigriventer envenomation, but also
reveals the potential natural resources that exist in venomous
fauna (particularly rich in Brazil) in terms of pharmacologically
active components.
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